{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:05:46Z","timestamp":1794485146198,"version":"4.9.1"},"reference-count":31,"publisher":"American Society of Hematology","issue":"11","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The efficacy and safety of acalabrutinib plus obinutuzumab and acalabrutinib monotherapy vs zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma without del(17p) were compared using an unanchored matching-adjusted indirect comparison. Individual patient-level data from ELEVATE-TN (acalabrutinib plus obinutuzumab, n\u00a0= 162; acalabrutinib monotherapy, n\u00a0=\u00a0163) were weighted to match published aggregate baseline data from SEQUOIA cohort 1, which excluded patients with del(17p) (zanubrutinib, n\u00a0= 241), using variables that were prognostic\/predictive of investigator-assessed progression-free survival (INV-PFS) in an exploratory Cox regression analysis of ELEVATE-TN. After matching, INV-PFS was longer with acalabrutinib plus obinutuzumab (hazard ratio [HR], 0.41; 95% confidence interval [CI], 0.23-0.74) and comparable with acalabrutinib monotherapy (HR, 0.91; 95%\u00a0CI, 0.53-1.56) vs zanubrutinib. Acalabrutinib monotherapy had significantly lower odds of any grade hypertension vs zanubrutinib (odds ratio [OR], 0.44; 95%\u00a0CI, 0.20-0.99), whereas acalabrutinib plus obinutuzumab had significantly higher odds of neutropenia (OR, 2.19; 95%\u00a0CI, 1.33-3.60) and arthralgia (OR, 2.33; 95%\u00a0CI, 1.37-3.96) vs zanubrutinib. No other significant differences in safety were observed. In summary, acalabrutinib plus obinutuzumab had longer INV-PFS with increased odds of neutropenia and arthralgia than zanubrutinib, whereas acalabrutinib monotherapy had similar INV-PFS with lower odds of any grade hypertension. These trials were registered at www.ClinicalTrials.gov as #NCT02475681 and #NCT03336333.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012142","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T16:02:03Z","timestamp":1712764923000},"page":"2861-2869","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":23,"title":["An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL"],"prefix":"10.1182","volume":"8","author":[{"given":"Adam S.","family":"Kittai","sequence":"first","affiliation":[{"name":"1Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-0899","authenticated-orcid":false,"given":"John N.","family":"Allan","sequence":"additional","affiliation":[{"name":"2Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"James","sequence":"additional","affiliation":[{"name":"3Polaris Biostatistics Ltd, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Bridge","sequence":"additional","affiliation":[{"name":"4AstraZeneca, Cambridge Biomedical Campus, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Miranda","sequence":"additional","affiliation":[{"name":"4AstraZeneca, Cambridge Biomedical Campus, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S. M.","family":"Yong","sequence":"additional","affiliation":[{"name":"5AstraZeneca, Gaithersburg, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady","family":"Fam","sequence":"additional","affiliation":[{"name":"4AstraZeneca, Cambridge Biomedical Campus, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Roos","sequence":"additional","affiliation":[{"name":"5AstraZeneca, Gaithersburg, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Shetty","sequence":"additional","affiliation":[{"name":"5AstraZeneca, Gaithersburg, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Skarbnik","sequence":"additional","affiliation":[{"name":"6Novant Health Cancer Institute, Lymphoma and CLL Program, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[{"name":"7Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"issue":"9","key":"2024061014105078600_bib1","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1080\/17474086.2021.1967139","article-title":"Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions","volume":"14","author":"Cho","year":"2021","journal-title":"Expert Rev Hematol"},{"issue":"26","key":"2024061014105078600_bib2","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"2024061014105078600_bib3","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2018-08-870238","article-title":"Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab","volume":"133","author":"Byrd","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2024061014105078600_bib4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): a covalent bruton tyrosine kinase inhibitor with a differentiated selectivity and in\u00a0vivo potency profile","volume":"363","author":"Barf","year":"2017","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"13","key":"2024061014105078600_bib5","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated with ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"2024061014105078600_bib6","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.hoc.2021.03.006","article-title":"Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: beyond ibrutinib","volume":"35","author":"Lasica","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"2024061014105078600_bib7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1124\/jpet.122.001116","article-title":"Identification and characterization of ACP-5862, the major circulating active metabolite of acalabrutinib: both are potent and selective covalent bruton tyrosine kinase inhibitors","volume":"384","author":"Podoll","year":"2023","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"31","key":"2024061014105078600_bib8","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024061014105078600_bib9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"2024061014105078600_bib10","author":"Sharman","year":"3-7  2022"},{"issue":"8","key":"2024061014105078600_bib11","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"key":"2024061014105078600_bib12","unstructured":"University of Bristol. NICE DSU technical support document (TSD) 18: methods for population-adjusted indirect comparisons in submission to NICE. 2016. Accessed 24 August 2023. https:\/\/research-information.bris.ac.uk\/en\/publications\/nice-dsu-technical-support-document-18-methods-for-population-adj."},{"key":"2024061014105078600_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-1-0716-1566-9_12","article-title":"Network meta-analysis","volume":"2345","author":"Watt","year":"2022","journal-title":"Methods Mol Biol"},{"issue":"1","key":"2024061014105078600_bib14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","article-title":"Network meta-analysis: an introduction for clinicians","volume":"12","author":"Rouse","year":"2017","journal-title":"Intern Emerg Med"},{"issue":"24","key":"2024061014105078600_bib15","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1182\/blood.2020009617","article-title":"Acalabrutinib in treatment-naive chronic lymphocytic leukemia","volume":"137","author":"Byrd","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2024061014105078600_bib16","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","article-title":"Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept","volume":"28","author":"Signorovitch","year":"2010","journal-title":"Pharmacoeconomics"},{"issue":"10232","key":"2024061014105078600_bib17","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"2024061014105078600_bib18","author":"Munir","year":"8-13  2023"},{"key":"2024061014105078600_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"2024061014105078600_bib20","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.3390\/cancers15071996","article-title":"Efficacy and safety of bruton tyrosine kinase inhibitor monotherapy compared with combination therapy for chronic lymphocytic leukemia and small lymphocytic lymphoma: a systematic review and meta-analysis","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers"},{"issue":"12","key":"2024061014105078600_bib21","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2024061014105078600_bib22","doi-asserted-by":"crossref","first-page":"e1505","DOI":"10.1002\/cnr2.1505","article-title":"Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia","volume":"5","author":"Samuels","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"issue":"9","key":"2024061014105078600_bib23","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"2024061014105078600_bib24","doi-asserted-by":"crossref","first-page":"E387","DOI":"10.1002\/ajh.27110","article-title":"A\u00a0matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"98","author":"Kittai","year":"2023","journal-title":"Am J Hematol"},{"issue":"26","key":"2024061014105078600_bib25","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"10129","key":"2024061014105078600_bib26","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","article-title":"Chronic lymphocytic leukaemia","volume":"391","author":"Hallek","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"2024061014105078600_bib27","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1007\/s12325-017-0564-1","article-title":"Comparative efficacy of ibrutinib versus obinutuzumab\u00a0+ chlorambucil in first-line treatment of chronic lymphocytic leukemia: a matching-adjusted indirect comparison","volume":"34","author":"Van Sanden","year":"2017","journal-title":"Adv Ther"},{"issue":"10","key":"2024061014105078600_bib28","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1080\/10428194.2021.1913144","article-title":"Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naive chronic lymphocytic leukemia","volume":"62","author":"Davids","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"2024061014105078600_bib29","unstructured":"National Institute for Health and Care Excellence. Acalabrutinib for treating chronic lymphocytic leukaemia [TA689]. 3 committee discussion. 2021. Accessed 24 August 2023. https:\/\/www.nice.org.uk\/guidance\/ta689\/chapter\/3-Committee-discussion."},{"issue":"3","key":"2024061014105078600_bib30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1017\/S0266462319000333","article-title":"Population adjustment methods for indirect comparisons: a review of National Institute for Health and Care excellence technology appraisals","volume":"35","author":"Phillippo","year":"2019","journal-title":"Int J Technol Assess Health Care"},{"issue":"3","key":"2024061014105078600_bib31","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/11\/2861\/2228449\/blooda_adv-2023-012142-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/11\/2861\/2228449\/blooda_adv-2023-012142-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T10:12:40Z","timestamp":1718014360000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/11\/2861\/515689\/An-indirect-comparison-of-acalabrutinib-with-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,6,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012142","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]}}}